Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2010
The significance of antibodies induced by therapeutically administered formulations of recombinant human interferon β (IFN-β) in multiple sclerosis (MS) has been a controversial topic since it was first reported in association with IFN-β-1b in 1993.1 Indeed, all current formulations of IFN-β are immunogenic (but in varying degrees) such that high titers of induced IFN-β neutralizing antibodies (NAb) do in fact neutralize in vitro IFN-β bioactivity. With regard to all currently available IFN-β—despite early, inconclusive, and often opposing studies—review of the world literature on this topic has allowed task forces of the European Federation of Neurological Societies2 and the American Academy of Neurology3 to agree on several important conclusions:
Phillips JT. Interferon Neutralizing Antibodies in Multiple SclerosisA New Perspective. Arch Neurol. 2010;67(4):386–387. doi:10.1001/archneurol.2010.31
Customize your JAMA Network experience by selecting one or more topics from the list below.